-
Something wrong with this record ?
Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1)
Á. Dombi, H. Kaci, K. Valentová, É. Bakos, C. Özvegy-Laczka, M. Poór
Language English Country United States
Document type Journal Article
Grant support
ÚNKP-23-4
Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
23-04654S
Grantová Agentura České Republiky
FK138184
Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
K138518
Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
BO/00381/21
Magyar Tudományos Akadémia
NLK
Directory of Open Access Journals
from 2013
Free Medical Journals
from 2013
PubMed Central
from 2013
ProQuest Central
from 2013-10-01
Open Access Digital Library
from 2013-01-01
Open Access Digital Library
from 2013-01-01
Health & Medicine (ProQuest)
from 2013-10-01
Wiley-Blackwell Open Access Titles
from 2013
ROAD: Directory of Open Access Scholarly Resources
from 2013
PubMed
39344282
DOI
10.1002/prp2.70021
Knihovny.cz E-resources
- MeSH
- Cytochrome P-450 CYP3A metabolism MeSH
- Cytochrome P-450 CYP2C9 metabolism MeSH
- Flavonoids * pharmacology MeSH
- Flavonols pharmacology MeSH
- Humans MeSH
- Liver-Specific Organic Anion Transporter 1 * metabolism MeSH
- Organic Anion Transporters * metabolism MeSH
- Serum Albumin metabolism MeSH
- Sulfates metabolism MeSH
- Cytochrome P-450 Enzyme System metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Myricetin (MYR) and ampelopsin (AMP, or dihydromyricetin) are flavonoid aglycones found in certain plants and dietary supplements. During the presystemic biotransformation of flavonoids, mainly sulfate and glucuronide derivatives are produced, which are the dominant metabolites in the circulation. In this study, we tested the interactions of MYR, myricetin-3'-O-sulfate (M3'S), AMP, and ampelopsin-4'-O-sulfate (A4'S) with human serum albumin (HSA), cytochrome P450 enzymes (CYPs), and organic anion-transporting polypeptides (OATPs) using in vitro models, including the recently developed method for measuring flavonoid levels in living cells. M3'S and MYR bound to albumin with high affinity, and they showed moderate displacing effects versus the Site I marker warfarin. MYR, M3'S, AMP, and A4'S exerted no or only minor inhibitory effects on CYP2C9, CYP2C19, and CYP3A4 enzymes. M3'S and MYR caused considerable inhibitory actions on OATP1B1 at low micromolar concentrations (IC50 = 1.7 and 6.4 μM, respectively), while even their nanomolar levels resulted in strong inhibitory effects on OATP2B1 (IC50 = 0.3 and 0.4 μM, respectively). In addition, M3'S proved to be a substrate of OATP1B1 and OATP2B1. These results suggest that MYR-containing dietary supplements may affect the OATP-mediated transport of certain drugs, and OATPs are involved in the tissue uptake of M3'S.
Department of Laboratory Medicine Medical School University of Pécs Pécs Hungary
Department of Pharmacology Faculty of Pharmacy University of Pécs Pécs Hungary
Doctoral School of Biology Institute of Biology Eötvös Loránd University Budapest Hungary
Institute of Microbiology of the Czech Academy of Sciences Prague Czech Republic
Molecular Medicine Research Group János Szentágothai Research Centre University of Pécs Pécs Hungary
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018726
- 003
- CZ-PrNML
- 005
- 20241024111245.0
- 007
- ta
- 008
- 241015s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/prp2.70021 $2 doi
- 035 __
- $a (PubMed)39344282
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Dombi, Ágnes $u Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
- 245 10
- $a Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1) / $c Á. Dombi, H. Kaci, K. Valentová, É. Bakos, C. Özvegy-Laczka, M. Poór
- 520 9_
- $a Myricetin (MYR) and ampelopsin (AMP, or dihydromyricetin) are flavonoid aglycones found in certain plants and dietary supplements. During the presystemic biotransformation of flavonoids, mainly sulfate and glucuronide derivatives are produced, which are the dominant metabolites in the circulation. In this study, we tested the interactions of MYR, myricetin-3'-O-sulfate (M3'S), AMP, and ampelopsin-4'-O-sulfate (A4'S) with human serum albumin (HSA), cytochrome P450 enzymes (CYPs), and organic anion-transporting polypeptides (OATPs) using in vitro models, including the recently developed method for measuring flavonoid levels in living cells. M3'S and MYR bound to albumin with high affinity, and they showed moderate displacing effects versus the Site I marker warfarin. MYR, M3'S, AMP, and A4'S exerted no or only minor inhibitory effects on CYP2C9, CYP2C19, and CYP3A4 enzymes. M3'S and MYR caused considerable inhibitory actions on OATP1B1 at low micromolar concentrations (IC50 = 1.7 and 6.4 μM, respectively), while even their nanomolar levels resulted in strong inhibitory effects on OATP2B1 (IC50 = 0.3 and 0.4 μM, respectively). In addition, M3'S proved to be a substrate of OATP1B1 and OATP2B1. These results suggest that MYR-containing dietary supplements may affect the OATP-mediated transport of certain drugs, and OATPs are involved in the tissue uptake of M3'S.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a flavonoidy $x farmakologie $7 D005419
- 650 12
- $a přenašeče organických aniontů $x metabolismus $7 D027361
- 650 12
- $a polypeptid C přenášející organické anionty $x metabolismus $7 D027381
- 650 _2
- $a cytochrom P-450 CYP3A $x metabolismus $7 D051544
- 650 _2
- $a flavonoly $x farmakologie $7 D044948
- 650 _2
- $a sírany $x metabolismus $7 D013431
- 650 _2
- $a sérový albumin $x metabolismus $7 D012709
- 650 _2
- $a cytochrom P450 CYP2C9 $x metabolismus $7 D065729
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kaci, Hana $u Drug Resistance Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, HUN-REN, Budapest, Hungary $u Doctoral School of Biology, Institute of Biology, Eötvös Loránd University, Budapest, Hungary
- 700 1_
- $a Valentová, Kateřina $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000277145350 $7 xx0034397
- 700 1_
- $a Bakos, Éva $u Drug Resistance Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, HUN-REN, Budapest, Hungary
- 700 1_
- $a Özvegy-Laczka, Csilla $u Drug Resistance Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, HUN-REN, Budapest, Hungary $1 https://orcid.org/0000000297216339
- 700 1_
- $a Poór, Miklós $u Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary $u Molecular Medicine Research Group, János Szentágothai Research Centre, University of Pécs, Pécs, Hungary $1 https://orcid.org/0000000314257459
- 773 0_
- $w MED00190080 $t Pharmacology research & perspectives $x 2052-1707 $g Roč. 12, č. 5 (2024), s. e70021
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39344282 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111239 $b ABA008
- 999 __
- $a ok $b bmc $g 2201536 $s 1230699
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 12 $c 5 $d e70021 $e - $i 2052-1707 $m Pharmacology research & perspectives $n Pharmacol Res Perspect $x MED00190080
- GRA __
- $a ÚNKP-23-4 $p Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
- GRA __
- $a 23-04654S $p Grantová Agentura České Republiky
- GRA __
- $a FK138184 $p Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
- GRA __
- $a K138518 $p Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
- GRA __
- $a BO/00381/21 $p Magyar Tudományos Akadémia
- LZP __
- $a Pubmed-20241015